Topic Archives: Stansberry Venture

Identifying Lashmet’s December 31, 2017 medical breakthrough: “Radical treatment that could treat 1 in 2 of all cancer patients”

Lots and lots and lots of you have been asking me about the big “cancer presentation” that the Stansberry folks made last night, which apparently was a combination of Dr. David Eifrig’s medical advice and forecasting and Dave Lashmet’s hinting about his “medical breakthrough” stock… so let’s get to it. I did not watch or […]

Zika & MERS Vaccine teaser solution: “My Best Idea Right Now” from Dave Lashmet at Stansberry Venture

Stansberry Venture is a high-end ($5,000/yr) newsletter that focuses on small “breakthrough” type companies, so far mostly in biotech and technology as far as I’ve seen. It’s the heir, roughly speaking, of Stansberry’s old Phase 1 newsletter that used to often pitch biotech, tech and junior mining stocks. It’s helmed by Dave Lashmet, who was […]

Answers: “The Most Disruptive Biotech Discovery of 2015-Confirmed Live: October 19th, 5:15 pm”

That’s a mysterious headline, right? The pitch we’re looking at today is from Dave Lashmet at Stansberry, who’s selling his Stansberry Venture newsletter for $5,000 — and the carrot he’s dangling to get you to subscribe is this “most disruptive biotech discovery” … which, it turns out, is a form of radiation therapy that, in […]

Comments

  • Avatar

    i am still having problems try to access stansberry venture value..if you cant help me, iwant a refunf!...

  • Avatar

    I am new to stansberry and so far I'm really impressed with the write ups. I like the full service brokerage program and...

  • Avatar

    Hi Travis, Hope all is well. During the recent discussion of their new offering, Stansberry Venture ...

  • Avatar

    I signed up for Stansberry Venture and was told I could get a deal at $5,000 for lifetime (normally $8.500 for a lifetim...

  • Avatar

    Great report; I love your logical approach and completely agree with your conclusions! I was wondering if you have seen...

  • Avatar

    Re: biotech mergers and acquisitions Although the surge in M&A activity has some observors warning of a "bubble" in ...

  • Avatar

    "One more thing!" -- Colombo I received this over the weekend from S & A Master Series: The four new gram-negat...

  • Avatar

    The Stansberry Venture group is teasing an antibiotic play that I imagine is one of ours. Any idea which one? http://pr...

  • Travis Johnson, Stock Gumshoe

    We don't publish Stansberry Venture, but we did write about one of their ads here: http://www.stockgumshoe.com/reviews/s...

  • Avatar

    I AM A SUB SCRIBER TO YOUR PERIODICAL AND AM VERY INTERESTED IN YOUR STANSBERRY VENTURE. HOW DO I INVEST IN THIS COMPANY...

  • Travis Johnson, Stock Gumshoe

    Careful about assuming the cause for a move -- there are many, many more people reading this free article than there are...

  • This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.

    Connect with Travis

    website designed by Gravity Switch